Showing 2,541 - 2,560 results of 2,811 for search '"pharmaceutical company"', query time: 0.59s Refine Results
  1. 2541

    COMPARATIVE PHARMACOEPIDEMIOLOGICAL ASSESSMENT OF ANTIHYPERTENSIVE DRUGS PRESCRIPTION IN OUTPATIENT PRACTICE IN KURSK AND CHISINAU by S. V. Povetkin, O. V. Levashova, V. I. Ghicavii, N. G. Batchinschi, L. A. Pjdgurschi, L. M. Turca

    Published 2018-07-01
    “…In Kursk, the ratio of these specified tactics of combined therapy was 53.5 and 34.1%, respectively. Among the pharmaceutical companies whose medicines were preferred by doctors in Kursk and in Chisinau, the leading positions were taken by KRKA (38.0 and 25.4%, respectively), Gideon Richter (13.5 and 28.7%, respectively) and Berlin-Chemie (26.7 and 15.6%, respectively).Conclusion. …”
    Get full text
    Article
  2. 2542

    Optimization of the production process for the anticancer lead compound illudin M: downstream processing by Lillibeth Chaverra-Muñoz, Theresa Briem, Stephan Hüttel

    Published 2022-08-01
    “…However, limitations related to the discovery and supply of these molecules by biotechnological means led to the retraction of big pharmaceutical companies from this field. The reasons included problems associated with strain culturing, screening, re-discovery, purification and characterization of novel molecules from natural sources. …”
    Get full text
    Article
  3. 2543

    Companies’ Health Technology Assessment Strategies and Practices in Australia, Canada, England, France, Germany, Italy and Spain: An Industry Metrics Study by Ting Wang, Ting Wang, Neil McAuslane, Lawrence Liberti, Helga Gardarsdottir, Wim Goettsch, Wim Goettsch, Hubert Leufkens

    Published 2020-12-01
    “…Background: Health technology assessment (HTA) has increased in importance in supporting payer decision making by assessing the relative effectiveness and cost effectiveness of new medicines. Thus, pharmaceutical companies need to address the HTA requirements early during development to improve reimbursement outcomes. …”
    Get full text
    Article
  4. 2544

    Phenotypic variation in biomass and related traits among four generations advanced lines of Cleome (Gynandropsis gynandra L. (Briq.)). by Aristide Carlos Houdegbe, Enoch G Achigan-Dako, E O Dêêdi Sogbohossou, M Eric Schranz, Alfred O Odindo, Julia Sibiya

    Published 2022-01-01
    “…Gynandropsis gynandra (spider plant) is an African traditional leafy vegetable rich in minerals, vitamins and health-promoting compounds with potential for health promotion, micronutrients supplementation and income generation for stakeholders, including pharmaceutical companies. However, information on biomass productivity is limited and consequently constrains breeders' ability to select high-yielding genotypes and end-users to make decisions on suitable cultivation and production systems. …”
    Get full text
    Article
  5. 2545
  6. 2546

    Does randomized evidence support sertraline as first-line antidepressant for adults with acute major depression? A systematic review and meta-analysis. by Cipriani, A, Furukawa, T, Geddes, J, Malvini, L, Signoretti, A, McGuire, H, Churchill, R, Nakagawa, A, Barbui, C

    Published 2008
    “…Reference lists of relevant papers and previous systematic reviews were hand-searched. Pharmaceutical companies and experts in this field were contacted for supplemental data. …”
    Journal article
  7. 2547

    Evaluation of an in silico cardiac safety assay: Using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge by Beattie, K, Luscombe, C, Williams, G, Munoz-Muriedas, J, Gavaghan, D, Cui, Y, Mirams, G

    Published 2013
    “…Introduction: Drugs that prolong the QT interval on the electrocardiogram present a major safety concern for pharmaceutical companies and regulatory agencies. Despite a range of assays performed to assess compound effects on the QT interval, QT prolongation remains a major cause of attrition during compound development. …”
    Journal article
  8. 2548

    Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data by Shinohara, K, Tanaka, S, Imai, H, Noma, H, Maruo, K, Cipriani, A, Yamawaki, S, Furukawa, T

    Published 2019
    “…<br/><strong>Methods: </strong>We identified all placebo-controlled, double-blind randomised controlled trials (RCTs) of second generation antidepressants for major depressive disorder conducted in Japan and requested their individual patient data (IPD) to pharmaceutical companies. We obtained IPD (n=1493) from four phase II/III RCTs comparing mirtazapine, escitalopram, duloxetine, paroxetine and placebo. …”
    Journal article
  9. 2549

    Recommendations for the reporting of harms in manuscripts on clinical trials assessing osteoarthritis drugs: A consensus statement from the European Society for Clinical and Econom... by Honvo, G, Bannuru, RR, Bruyère, O, Rannou, F, Herrero-Beaumont, G, Uebelhart, D, Cooper, C, Arden, N, Conaghan, PG, Reginster, J-Y, Thomas, T, McAlindon, T

    Published 2019
    “…CONCLUSIONS:These recommendations may contribute to improve transparency in the field of safety of anti-OA medications. Pharmaceutical companies developing drugs for OA, and researchers conducting clinical trials, are encouraged to comply with them when reporting harms-related results in manuscripts on RCTs. …”
    Conference item
  10. 2550

    Identification of Bioactive Compounds from Marine Natural Products and Exploration of Structure-Activity Relationships (SAR) by Mojdeh Dinarvand, Malcolm Spain

    Published 2021-03-01
    “…This method is a novel strategy to overcome insufficient quantities of pure material (NPs) for drug discovery and development which is a big challenge for pharmaceutical companies. The antibacterial screening of the marine extracts has shown several of the compounds exhibited potent in-vitro antibacterial activity, especially against methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) with minimum inhibitory concentration (MIC) values between 15.6 to 62.5 microg mL<sup>−1</sup>. …”
    Get full text
    Article
  11. 2551

    Attitudes towards the COVID-19 Vaccine and Willingness to Get Vaccinated among Healthcare Workers in French Guiana: The Influence of Geographical Origin by Nicolas Vignier, Kepha Brureau, Sybille Granier, Jacques Breton, Céline Michaud, Mélanie Gaillet, Camille Agostini, Mathilde Ballet, Mathieu Nacher, Audrey Valdes, Philippe Abboud, Antoine Adenis, Félix Djossou, Loïc Epelboin, Maylis Douine

    Published 2021-06-01
    “…Conversely, participants were less likely to have been vaccinated or willing to if they were nurses or of another non-medical profession, born in French Guiana, feared adverse effects, or if they did not trust pharmaceutical companies and management of the epidemic by authorities. …”
    Get full text
    Article
  12. 2552

    Neglected Tropical Diseases and the Millennium Development Goals-why the "other diseases" matter: reality versus rhetoric by Molyneux David H, Malecela Mwele N

    Published 2011-12-01
    “…This has been made possible by donations from major pharmaceutical companies of quality and efficacious drugs which have a proven track record of safety. …”
    Get full text
    Article
  13. 2553

    Quality assurance in non-interventional studies by Capan, Müge, Theobald, Karlheinz, Schinzel, Stefan, Herbold, Marlis, Hundt, Ferdinand

    Published 2009-11-01
    “…In addition in Germany the Federal Institute for Drugs and Medical Devices (BfArM) together with the Paul Ehrlich Institute (PEI) and the German Association of Research-Based Pharmaceutical Companies (VFA) have published respectively recommendations dealing with quality aspects of non-interventional observational studies. …”
    Get full text
    Article
  14. 2554

    Hesitancy to COVID-19 Vaccines among University Students in Lebanon by M. Bou Hamdan, S. Singh, M. Polavarapu, T. Jordan, N. Melhem

    Published 2022-03-01
    “…Students reporting that pharmaceutical companies adequately tested the safety of the vaccine (OR=0.52; 95% CI=0.19-1.43; p value=0.21) and those who consider the vaccine in agreement with their personal views (OR= 0.11, 95% CI= 0.02-0.51, p value= 0.004) were less likely to be hesitant. …”
    Get full text
    Article
  15. 2555

    Evaluation of GDF15 as a therapeutic target of cardiometabolic diseases in human: A Mendelian randomization studyResearch in context by Ching-Lung Cheung, Kathryn C.B. Tan, Philip C.M. Au, Gloria H.Y. Li, Bernard M.Y. Cheung

    Published 2019-03-01
    “…Although many pharmaceutical companies are developing drugs targeting GFRAL, whether the findings from animal studies can be extrapolated to man is unknown. …”
    Get full text
    Article
  16. 2556
  17. 2557

    Complementary and Alternative Medicines in Northern Cyprus: Public Awareness, Patterns of Use, and Attitudes by Doğa Ünlüyol, Hüseyin Gökçekuş, Youssef Kassem, Murat Tezer, Filiz Meriçli, Dudu Özkum Yavuz

    Published 2023-03-01
    “…Given our finding that dissatisfaction with modern medicine is the most important reason for the preferred use of herbal medicines, government agencies, physicians, and pharmaceutical companies should be aware of this issue and should aim to create some level of awareness among users.…”
    Get full text
    Article
  18. 2558

    The Quality of Instructional YouTube Videos for the Administration of Intranasal Spray: Observational Study by Peters-Geven, Marije M, Rollema, Corine, Metting, Esther I, van Roon, Eric N, de Vries, Tjalling W

    Published 2020-12-01
    “…ResultsWe identified 33 YouTube videos made by different health care professionals and pharmaceutical companies around the world. None of the videos displayed all the steps correctly, while 5 of the 33 (15%) videos displayed over 75% of the steps correctly. …”
    Get full text
    Article
  19. 2559

    Intranasal Corticosteroids for the Medical Management of Nasal Polyps in Adults: a Meta-Analysis by Natividad A. Almazan-Aguilar

    Published 2007-11-01
    “…Search Strategy: Comprehensive search of Cochrane's Controlled Trials Registry (CCTR) Issue 2, 2003, Medline 1966 to 2002, and Embase 1974 - 2002 bibliographic review, requests for information from authors and pharmaceutical companies.   Data collection and analysis:  Sixteen studies were evaluated for inclusion, and trial quality, validity assessment, and completion of data extraction were done. …”
    Get full text
    Article
  20. 2560

    State capture through indemnification demands? Effects on equity in the global distribution of COVID-19 vaccines by Ariel Gorodensky, Jillian C. Kohler

    Published 2022-12-01
    “…Background State capture by the pharmaceutical industry is a form of corruption whereby pharmaceutical companies shift laws or policies about their products away from the best interest of the public and toward their private benefit. …”
    Get full text
    Article